14685-90-6

Basic information

• Product Name: 4-HYDRAZINO-BENZOIC ACID ETHYL ESTER
• Synonyms: ethyl 4-hydrazinobenzoate(SALTDATA: HCl);4-(1-ethylhydrazin-1-yl)benzoate;Benzoic acid, 4-hydrazino-, ethyl ester;Benzoic acid,4-hydrazinyl-, ethyl ester
• CAS NO: 14685-90-6
• Molecular Formula: C₉H₁₂N₂O₂
• Molecular Weight: 180.2
• Mol File: 14685-90-6.mol
• Article Data: 9

Chemical Properties

• Melting Point: 118 °C
• Boiling Point: 329.9°C at 760 mmHg
• Flash Point: 153.3°C
• Appearance: /
• Density: 1.197g/cm³
• Vapor Pressure: 0.000172mmHg at 25°C
• Refractive Index: 1.595
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 4.39±0.20(Predicted)
• CAS DataBase Reference: 4-HYDRAZINO-BENZOIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDRAZINO-BENZOIC ACID ETHYL ESTER(14685-90-6)
• EPA Substance Registry System: 4-HYDRAZINO-BENZOIC ACID ETHYL ESTER(14685-90-6)

Safety Data

• Hazardous Substances Data: 14685-90-6(Hazardous Substances Data)

Usage

Uses

Ethyl 4-Hydrazinylbenzoate can be used to treat alzheimer’s disease.

InChI:InChI=1/C9H12N2O2/c1-2-13-9(12)7-3-5-8(11-10)6-4-7/h3-6,11H,2,10H2,1H3

Upstream product

• 40566-85-6 4-ethoxycarbonylphenylhydrazine hydrochloride 
• 94-09-7 p-aminoethylbenzoate 
• 619-67-0 4-Hydrazinobenzoic acid 
• 64-17-5 ethanol 
• 93-89-0 benzoic acid ethyl ester 

Downstream Products

• 84456-05-3 4-semicarbazido-benzoic acid ethyl ester 
• 93574-69-7 p-hydrazinobenzoic acid hydrazide 
• 101094-06-8 ethyl 4-(phenylsulfonyl)benzoate 
• 1330540-11-8 C₂₃H₁₇Cl₂NO₃ 
• 201530-41-8 deferasirox 
• 7272-54-0 2-(5-Carboethoxy-1H-indol-3-yl)ethylamine 
• 89593-76-0 C₁₃H₁₀Cl₂N₂O₃ 
• 1415356-11-4 C₂₀H₁₇ClN₂O₅ 
• 201530-79-2 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid ethyl ester 
• 1242144-88-2 (+/-)-4-{1-[4-(ethoxycarbonyl)phenyl]-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-3-yl}benzoic acid 
• 74470-87-4 5-ethoxycarbonyl-2,3,3-trimethylindolenine 
• 1208251-53-9 ethyl 4-{5-[2-(2,6,6-trimethylcyclohex-2-en-1-yl)ethenyl]-1H-pyrazol-1-yl}benzoate 
• 1208251-77-7 ethyl 4-{3-[2-(2,6,6-trimethylcyclohex-2-en-1-yl)ethenyl]-1H-pyrazol-1-yl}benzoate 
• 94-09-7 p-aminoethylbenzoate 

Relevant articles and documents

SUBSTITUTED SULFONYL HYDRAZIDES AS INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY

The present invention relates to substituted sulfonyl hydrazides that have the ability to inhibit lysine biosynthesis via the diaminopimelate pathway in certain organisms. As a result of this activity these compounds can be used in applications where inhibition of lysine biosynthesis is useful applications of this type include the use of the compound as herbicides and/or anti- bacterial agents.

5-LIPOXYGENASE INHIBITORS

The present invention relates to pyrazole derivatives of formula 1 and to process as for their synthesis as 5-lipoxygenase (5-LO) inhibitors. The present invention also relates to pharmacological compositions containing these pyrazole derivatives, as well as, methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, Type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders.

Discovery of (3 S,3a R)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5- tetrahydro-2 H -benzo[ g ]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy

We have discovered a novel class of nonsteroidal pyrazoline antagonists of the mineralocorticoid receptor (MR) that show excellent potency and selectivity against other nuclear receptors. Early analogues were poorly soluble and had a propensity to inhibit the hERG channel. Remarkably, both of these challenges were overcome by incorporation of a single carboxylate moiety. Structural modification of carboxylate-containing lead R-4g with a wide range of substituents at each position of the pyrazoline ring resulted in R-12o, which shows excellent activity against MR and reasonable pharmacokinetic profile. Introduction of conformational restriction led to a novel series characterized by exquisite potency and favorable steroid receptor selectivity and pharmacokinetic profile. Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt sensitive preclinical model of salt-induced hypertension and nephropathy showed blood pressure attenuation significantly greater than that with eplerenone, reduction in urinary albumin, and renal protection. As a result of these findings, 3S,3aR-27d was advanced to clinical studies.